

Inventor(s): Darrell R. Anderson et al.

Group Art Unit 1644

Examiner: R. Schwadron

Appl. No.: 08 921,060

Atty. Dkt. P 0275463 1992-30-0029CP2

Series Code ↑

Serial No. ↑

Filed: August 29, 1997

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

RECEIVED

AUG 10 2001

TECH CENTER 1600/2900

Appn. Title: Therapeutic Application of Chimeric and
Radiolabeled Antibodies to Human B
Lymphocyte Restricted Differentiation
Antigen for Treatment of B Cell
Lymphoma

Date: August 8, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☐ NOT made
B. ☒ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See **Required
Separate Paper**
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	20	**minus 20	0	x \$18/\$9 = + \$0	103/203
3. Independent Claims	2	***minus 3	0	x \$80/\$40 = + \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add				+ \$270/\$135 = + \$0	104/204
5. Original due Date: August 16, 2001		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) (2 mos) (3 mos) (Usable only for ≤ 2mo.OA --- 4 mos) (Usable only for 30 day/1mo.OA --- 5 mos)	\$110/\$55 = \$390/\$195 = \$890/\$445 = \$1390/\$695= \$1890/\$945=	+ \$0	115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract				- \$0	
8. Extension Fee Attached				+ \$0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee				+ \$110/\$55	+ \$0 148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add				+ \$180	+ \$0 126
or if Rule 97(d) Request add				+ \$180	+ \$0 126
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$710/355	+ \$0 146/246
12. No. of additional inventions for examination per Rule 129(b).....				x \$710/355 ea	+ \$0 149/249
13. Request for Continued Examination (RCE)				+ \$710/355	+ \$0 1179/1279
14. Petition fee for				+ \$0	
15. TOTAL FEE ENCLOSED =				\$0	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275463

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

1600 Tysons Boulevard

By Atty: Bonnie D. Weiss

Reg. No. 43,255

McLean, VA 22102

Sig:

Fax: (703) 905-2500

Tel: (703) 905-2000

Tel: (703) 905-2219

Atty/Sec: BDW/kmh

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



RECEIVED

AUG 10 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#33
8/13/01

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

* * * * *

AMENDMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Communication from the Examiner dated July 16, 2001, kindly enter the following remarks.

Remarks

According to the Communication dated July 16, 2001, the Reply filed April 24, 2001 was not fully responsive to the prior Office Action in that a specific response to the rejection under 35 U.S.C. §103(a) set forth under paragraph (10) of the Office Action was omitted. Applicants appreciate the Examiner's acknowledging this inadvertent admission, which is now submitted herein.

As set forth in paragraph (10) of the Office Action, claims 11-15 were rejected under 35 U.S.C. §103(a) as being allegedly unpatentable over Hellstrom et al. (WO 92/07466) in view of Robinson et al. (U.S. Patent 5,500,362), Reff et al. (J. Biol. Chem., March 29, 1993) or Reff et al. (Blood, Jan. 15, 1994) or Anderson et al. (1991 abstract). It is the Examiner's opinion that the claims of the present invention would be obvious in view of this combination of references given that Hellstrom et al. allegedly teaches the use of chimeric antibodies in combination with chemotherapeutic agents for the treatment of cancer, Robinson et al. allegedly teaches the use of chimeric anti-CD20 antibody to treat B cell lymphoma, and that the Reff references and Anderson et al. allegedly disclose the specific chimeric anti-CD20